{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T19:22:29Z","timestamp":1746386549147},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-024-05939-4","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T03:39:04Z","timestamp":1726803544000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase"],"prefix":"10.1007","volume":"150","author":[{"given":"JingCheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SiSi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HuiXian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"5939_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-020-0215-2","volume":"21","author":"A Baluapuri","year":"2020","unstructured":"Baluapuri A, Wolf E (2020) Target gene-independent functions of MYC oncoproteins. Nature Rev Mol Cell Biol 21:255\u2013267. https:\/\/doi.org\/10.1038\/s41580-020-0215-2","journal-title":"Nature Rev Mol Cell Biol"},{"key":"5939_CR2","doi-asserted-by":"crossref","unstructured":"Bednarski JJ, Sleckman BP (2019) At the intersection of DNA damage and immune responses. Nature Rev Immunol","DOI":"10.1038\/s41577-019-0135-6"},{"key":"5939_CR3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41418-018-0142-3","volume":"26","author":"M Bittremieux","year":"2019","unstructured":"Bittremieux M et al (2019) Constitutive IP(3) signaling underlies the sensitivity of B-cell cancers to the Bcl-2\/IP(3) receptor disruptor BIRD-2. Cell Death Diff 26:531\u2013547. https:\/\/doi.org\/10.1038\/s41418-018-0142-3","journal-title":"Cell Death Diff"},{"key":"5939_CR4","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","volume":"16","author":"S Cl\u00e9mentine","year":"2015","unstructured":"Cl\u00e9mentine S, Alexandra TG, Bertrand C (2015) Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas. Lancet Oncol 16:e555\u2013e567","journal-title":"Lancet Oncol"},{"key":"5939_CR5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.tcb.2022.07.006","volume":"33","author":"SK Das","year":"2023","unstructured":"Das SK, Lewis BA, Levens D (2023) MYC: a complex problem. Trends Cell Biol 33:235\u2013246. https:\/\/doi.org\/10.1016\/j.tcb.2022.07.006","journal-title":"Trends Cell Biol"},{"key":"5939_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jcb.24358","volume":"114","author":"M Davide","year":"2013","unstructured":"Davide M, Annalisa R, Flavio R, Antonio G (2013) Emerging molecular networks in Burkitt\u2019s lymphoma. J Cell Biochem 114:35\u201338","journal-title":"J Cell Biochem"},{"key":"5939_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","volume":"19","author":"R Dhanasekaran","year":"2022","unstructured":"Dhanasekaran R, Deutzmann A (2022) The MYC oncogene\u2014the grand orchestrator of cancer growth and immune evasion. Nature Rev Clin Oncol 19:23\u201336. https:\/\/doi.org\/10.1038\/s41571-021-00549-2","journal-title":"Nature Rev Clin Oncol"},{"key":"5939_CR8","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/eji.200324133","volume":"33","author":"A Durandy","year":"2003","unstructured":"Durandy A (2003) Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur J Immunol 33:2069","journal-title":"Eur J Immunol"},{"key":"5939_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.semcancer.2020.11.008","volume":"83","author":"H Fatma","year":"2022","unstructured":"Fatma H, Maurya SK, Siddique HR (2022) Epigenetic modifications of c-MYC: role in cancer cell reprogramming, progression and chemoresistance. Semin Cancer Biol 83:166\u2013176. https:\/\/doi.org\/10.1016\/j.semcancer.2020.11.008","journal-title":"Semin Cancer Biol"},{"key":"5939_CR10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","volume":"130","author":"JW Friedberg","year":"2017","unstructured":"Friedberg JW (2017) How I treat double-hit lymphoma. Blood 130:590\u2013596","journal-title":"Blood"},{"key":"5939_CR11","doi-asserted-by":"publisher","first-page":"909008","DOI":"10.3389\/fimmu.2022.909008","volume":"13","author":"E Gonz\u00e1lez Barca","year":"2022","unstructured":"Gonz\u00e1lez Barca E (2022) Role of bispecific antibodies in relapsed\/refractory diffuse large B-cell lymphoma in the CART era. Front Immunol 13:909008. https:\/\/doi.org\/10.3389\/fimmu.2022.909008","journal-title":"Front Immunol"},{"key":"5939_CR12","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30:3460\u20133467","journal-title":"J Clin Oncol"},{"key":"5939_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.cell.2014.11.013","volume":"159","author":"Q Jason","year":"2014","unstructured":"Jason Q et al (2014) B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. Cell 159:1524\u20131537","journal-title":"Cell"},{"key":"5939_CR14","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3109\/10428194.2014.981172","volume":"56","author":"N Johnson-Farley","year":"2015","unstructured":"Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR (2015) ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in \u201cdouble hit\u201d lymphoma cells. Leuk Lymphoma 56:2146\u20132152","journal-title":"Leuk Lymphoma"},{"key":"5939_CR15","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/blood-2011-01-327932","volume":"119","author":"T Kawamata","year":"2012","unstructured":"Kawamata T et al (2012) Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. Blood 119:3123\u20133127","journal-title":"Blood"},{"key":"5939_CR16","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/blood-2011-01-327932","volume":"119","author":"T Kawamata","year":"2012","unstructured":"Kawamata T, Lu J, Sato T, Tanaka M, Kotani A (2012) Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor. Blood 119:3123\u20133127","journal-title":"Blood"},{"key":"5939_CR17","doi-asserted-by":"crossref","unstructured":"Kumar et al (2018) Regulation of the DNA repair complex during somatic hypermutation and class-switch recombination. J Immunol Off J Am Assoc Immunol","DOI":"10.4049\/jimmunol.1701586"},{"key":"5939_CR18","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","volume":"20","author":"R Kuppers","year":"2001","unstructured":"Kuppers R, Dalla-Favera R (2001) Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20:5580\u20135594","journal-title":"Oncogene"},{"key":"5939_CR19","first-page":"1","volume":"122","author":"AJ Matthews","year":"2013","unstructured":"Matthews AJ, Zheng S, Dimenna LJ, Chaudhuri J (2013) Regulation of immunoglobulin class-switch recombination: choreography of noncoding transcription, targeted DNA deamination, and long-range DNA repair. Adv Immunol 122:1\u201357","journal-title":"Adv Immunol"},{"key":"5939_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/nrc2231","volume":"8","author":"N Meyer","year":"2009","unstructured":"Meyer N, Penn LZ (2009) Reflecting on 25 years with MYC. Nature Rev Cancer 8:976\u2013990","journal-title":"Nature Rev Cancer"},{"key":"5939_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1182\/blood.2019003014","volume":"135","author":"HV Nguyen","year":"2020","unstructured":"Nguyen HV et al (2020) Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis. Blood 135:1019\u20131031. https:\/\/doi.org\/10.1182\/blood.2019003014","journal-title":"Blood"},{"key":"5939_CR22","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"5939_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/ng.2007.35","volume":"40","author":"L Pasqualucci","year":"2008","unstructured":"Pasqualucci L (2008) AID is required for germinal center-derived lymphomagenesis. Nature Genet 40:108\u2013112","journal-title":"Nature Genet"},{"key":"5939_CR24","unstructured":"Paul et al. (2015) Nilotinib versus imatinib for GIST. Lancet Oncol"},{"key":"5939_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/ejh.12212","volume":"92","author":"M\u00d8 Pederson","year":"2013","unstructured":"Pederson M\u00d8 et al (2013) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC - or double-hit MYC \/ BCL 2 translocations. Eur J Haematol 92:42\u201348","journal-title":"Eur J Haematol"},{"key":"5939_CR26","doi-asserted-by":"publisher","first-page":"eabj5502","DOI":"10.1126\/science.abj5502","volume":"377","author":"M Peycheva","year":"2022","unstructured":"Peycheva M, Neumann T (2022) DNA replication timing directly regulates the frequency of oncogenic chromosomal translocations. Science 377:eabj5502. https:\/\/doi.org\/10.1126\/science.abj5502","journal-title":"Science"},{"key":"5939_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/1947601910377494","volume":"1","author":"EV Prochownik","year":"2010","unstructured":"Prochownik EV, Vogt PK (2010) Therapeutic targeting of Myc. Genes Cancer 1:650\u2013659","journal-title":"Genes Cancer"},{"key":"5939_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature04495","volume":"440","author":"AR Ramiro","year":"2006","unstructured":"Ramiro AR (2006) Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440:105\u2013109","journal-title":"Nature"},{"key":"5939_CR29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/sj.leu.2404183","volume":"20","author":"L Reiniger","year":"2006","unstructured":"Reiniger L et al (2006) Richter\u2019s and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. Leukemia 20:1089\u20131095","journal-title":"Leukemia"},{"key":"5939_CR30","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/35015097","volume":"405","author":"C Richardson","year":"2000","unstructured":"Richardson C, Jasin M (2000) Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 405:697\u2013700","journal-title":"Nature"},{"key":"5939_CR31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cell.2008.09.062","volume":"135","author":"DF Robbiani","year":"2008","unstructured":"Robbiani DF et al (2008) AID is required for the chromosomal breaks in c-myc that lead to c-myc\/IgH translocations. Cell 135:1028\u20131038","journal-title":"Cell"},{"key":"5939_CR32","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Da WH, Johnson CA, Staudt LM (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396\u20131407","journal-title":"N Engl J Med"},{"key":"5939_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1349-7006.2011.02186.x","volume":"103","author":"H Shikata","year":"2012","unstructured":"Shikata H et al (2012) Role of activation-induced cytidine deaminase in the progression of follicular lymphoma. Cancer Sci 103:415\u2013421","journal-title":"Cancer Sci"},{"key":"5939_CR34","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nsmb.1884","volume":"17","author":"Z Xu","year":"2010","unstructured":"Xu Z et al (2010) 14-3-3 adaptor proteins recruit AID to 5\u2019-AGCT-3\u2019-rich switch regions for class switch recombination. Nature Struct Mol Biol 17:1124\u20131135","journal-title":"Nature Struct Mol Biol"},{"key":"5939_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-71058-y","author":"J Zhang","year":"2020","unstructured":"Zhang J, Shi Y, Zhao M, Hu H, Huang H (2020) Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-020-71058-y","journal-title":"Sci Rep"},{"key":"5939_CR36","doi-asserted-by":"publisher","first-page":"112360","DOI":"10.1016\/j.biopha.2021.112360","volume":"144","author":"L Zhao","year":"2021","unstructured":"Zhao L et al (2021) The endocytic pathway of Pt nanoclusters and their induced apoptosis of A549 and A549\/Cis cells through c-Myc\/p53 and Bcl-2\/caspase-3 signaling pathways. Biomed Pharmacother 144:112360. https:\/\/doi.org\/10.1016\/j.biopha.2021.112360","journal-title":"Biomed Pharmacother"},{"key":"5939_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-022-01249-9","volume":"15","author":"Y Zhuang","year":"2022","unstructured":"Zhuang Y et al (2022) Altered pathways and targeted therapy in double hit lymphoma. J Hematol Oncol 15:26. https:\/\/doi.org\/10.1186\/s13045-022-01249-9","journal-title":"J Hematol Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05939-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05939-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05939-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T03:35:38Z","timestamp":1728444938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05939-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["5939"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05939-4","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest. No disclosures were reported by all the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by the ethics committee of Affiliated Jinhua Hospital, Zhejiang University School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"426"}}